Investigational Drug
ABBV-706
TrialFetch AI Analysis
Show TrialFetch AI Analysis
Overview
ABBV-706 is an investigational antibody–drug conjugate being studied for advanced cancers, particularly relapsed or refractory small-cell lung cancer (SCLC). Human results are available from an open-label phase 1 trial, but its clinical benefit has not yet been established in a controlled efficacy trial. (pmc.ncbi.nlm.nih.gov)
Mechanism of action
ABBV-706 targets SEZ6, a protein expressed in many SCLC tumors. After the antibody–drug conjugate enters a cell, it releases a topoisomerase-1 inhibitor intended to cause DNA damage and cell death. (pmc.ncbi.nlm.nih.gov)
Efficacy
Among 124 patients with relapsed or refractory SCLC who received ABBV-706 alone, the investigator-assessed objective response rate was 52% (65/124). Median response duration was 5.3 months, median progression-free survival was 5.4 months, and median overall survival was 11.3 months. A smaller second-line group receiving 1.8 mg/kg had an 82% response rate (14/17); that estimate needs confirmation in larger studies. These are single-arm results, so they do not establish how ABBV-706 compares with other treatments. (pmc.ncbi.nlm.nih.gov)
Safety
Among 240 patients receiving ABBV-706 alone, the most common treatment-related adverse events were anemia (61%) and fatigue (38%); 61% had a grade 3 or higher treatment-related event. Drug-related pneumonitis or interstitial lung disease was reported in 4%. Investigators considered three deaths treatment-related: two from pneumonitis and one associated with a decreased platelet count. (pmc.ncbi.nlm.nih.gov)
Further reading
Last updated: Sep 2026
Active trials using ABBV-706
Found 2 active trials using this drug:
TrialFetch AI summary: Adults with relapsed or refractory SCLC after prior systemic therapy, generally including platinum-etoposide plus a checkpoint inhibitor when eligible and tarlatamab, are randomized to intravenous ABBV-706 or investigator-selected topotecan, lurbinectedin, or amrubicin. ABBV-706 is an investigational SEZ6-targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor payload.
ClinicalTrials.gov ID: NCT07365241
TrialFetch AI summary: Adults with previously untreated extensive-stage SCLC, ECOG performance status 0–1, and measurable disease receive first-line ABBV-706 plus atezolizumab or carboplatin, etoposide, and atezolizumab, with optional lurbinectedin. ABBV-706 is an investigational SEZ6-targeting antibody–drug conjugate that delivers a topoisomerase-1 inhibitor.
ClinicalTrials.gov ID: NCT07155174
